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Abstract
Epidemiological studies have shown an inverse association between high-
density lipoprotein cholesterol (HDL-C) levels and risk of ischemic heart dis-
ease. In addition, a low level of HDL-C has been shown to be a risk factor for
other diseases not related to atherosclerosis. However, recent studies have not
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supported a causal effect of HDL-C in the development of atherosclerosis.
Furthermore, new drugs markedly elevating HDL-C levels have been disap-
pointing with respect to clinical endpoints. Earlier, most studies have focused
almost exclusively on the total HDL-C without regard to the chemical composi-
tion or multiple subclasses of HDL particles. Recently, there have been efforts to
dissect the HDL fraction into as many well-defined subfractions and individual
molecules of HDL particles as possible. On the other hand, the focus is shifting
from the structure and composition to the function of HDL particles. Biomarkers
and mechanisms that could potentially explain the beneficial characteristics of
HDL particles unrelated to their cholesterol content have been sought with
sophisticated methods such as proteomics, lipidomics, metabonomics, and func-
tion studies including efflux capacity. These new approaches have been used in
order to resolve the complex effects of diseases, conditions, environmental
factors, and genes in relation to the protective role of HDL but high-throughput
methods are still needed for large-scale epidemiological studies.
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Low levels of high-density lipoprotein (HDL) particles in the plasma of patients
with coronary heart disease (CHD) were observed already in the early 1950s (Barr
et al. 1951; Nikkila¨ 1953). At that time the lipoprotein fraction was called alpha
lipoprotein as electrophoresis methods were used. Twenty years later the same
relationship was confirmed in large epidemiological studies using ultracentrifuga-
tion or precipitation methods. The new interest for HDL research was then
stimulated by the reverse cholesterol transport hypothesis (Glomset et al. 1966)
and a Lancet review written by Miller and Miller (1975). These authors proposed
that low plasma HDL concentration accelerates the development of atherosclerosis
by impairing the clearance of cholesterol from the arterial wall.
1 Protective Role of HDL: Evidence from Epidemiological
Studies
The protective role of HDL has been well established in several epidemiological
studies. An increment of 2.5 % corresponding to 1 mg/dl or 0.04 mmol/l is
associated with a 2 and 3 % reduction in CHD risk in men and women, respectively
(Gordon et al. 1989; Jacobs et al. 1990). So far, it is mainly the total cholesterol
concentration in HDL particles that has been determined using standardized
methods applicable also to routine clinical work. However, cholesterol represents
only a small fraction, approximately 15 %, of the HDL particle mass. Furthermore,
the proportion of free cholesterol to esterified cholesterol varies between lipopro-
tein particles.
The relationship between HDL-C and CHD is complex and HDL-C may not be
an appropriate indicator of the impact of this lipoprotein fraction on cardiovascular
risk. This has been demonstrated, e.g., by the fact that carotid intima media
thickness is not increased in apoA-I(Milano) mutation carriers with very low levels
of HDL-C (Sirtori et al. 2001). Moreover, recently, drugs that increase HDL
cholesterol (HDL-C) level have failed to reduce cardiovascular risk, and Mendelian
randomization studies have failed to show a causal relationship between HDL-C
and cardiovascular diseases (van Capelleveen et al. 2013).
Despite this controversy, the hard evidence for low HDL-C level as a risk factor
of atherosclerosis will be described in the first part of this presentation. It is
noteworthy that the cholesterol concentration in HDL fraction is not necessarily
associated with the antiatherogenic properties of HDL. Therefore, later in this
chapter, other potential HDL-related biomarkers for the prevention of atheroscle-
rosis by HDL will be presented. These include not only the other major lipid and
apolipoprotein components of HDL but also minor bioactive lipid molecules
residing in the HDL particles. Furthermore, the physicochemical characteristics
of various subfractions of HDL as well as the large number of molecules circulating
more or less firmly bound to HDL particles may contribute to the antiatherogenic
potential of HDL via antioxidative and anti-inflammatory effects or cholesterol
transport capacity.
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2 HDL Cholesterol as a Risk Factor for Atherosclerosis
and Its Complications
Until recently, the clinical evaluation of HDL as a risk factor has focused almost
exclusively on the total HDL-C without regard to the chemical composition or
multiple subclasses of HDL particles. A large body of epidemiological research has
shown a solid inverse and independent relationship between HDL-C and the risk of
cardiovascular disease (Toth et al. 2013).
Gofman et al. first reported an inverse association between HDL-C levels and the
risk of ischemic heart disease (Gofman et al. 1966). This was shown in case–control
studies from Framingham and Livermore cohorts with 10–12 years of follow-up.
Later, the inverse relationship has been observed also in several larger studies in the
USA (the Honolulu Heart Program, Rhoads et al. 1976, and the Framingham Heart
Study, Gordon et al. 1977), in Norway (the Tromsø Heart Study, Miller et al. 1977),
in Germany (the Prospective Cardiovascular Mu¨nster Study, Assmann et al. 1996),
and in Israel (the Israeli Ischemic Heart Disease Study, Goldbourt et al. 1997).
Recent meta-analyses have corroborated the relationship between HDL-C and
atherosclerosis and its complications (Chirovsky et al. 2009; Boekholdt
et al. 2013; Touboul et al. 2014). The association is independent of triglyceride
levels and other risk factors (Goldbourt et al. 1997). Many CHD risk algorithms
have included HDL-C as a factor to improve the prediction of CHD events (Cooper
et al. 2005; Halcox et al. 2013; Hippisley-Cox et al. 2013; Tehrani et al. 2013).
Recently, the picture has become less clear. Mendelian randomization studies
have not supported a causal effect of HDL-C in the atherosclerotic disease process
(Voight et al. 2012; Holmes et al. 2014). Moreover, statin trials have shown that
HDL-C is predictive among patients treated with statin even at low LDL levels
(Barter et al. 2007), whereas it is not predictive among patients taking placebo
(Ridker et al. 2010; Mora et al. 2012). Further research is needed to clarify the role
of HDL-C as a risk factor. It is possible that other characteristics of HDL particles
may be more important in this respect than the total cholesterol concentration.
In patients with CHD, the protective role of HDL-C is controversial (Silbernagel
et al. 2013). Some studies have shown that low HDL-C is associated with athero-
sclerotic progression in myocardial infarction survivors (Johansson et al. 1991;
Duffy et al. 2012; Liosis et al. 2013), provides additional prognostic value also in
patients with acute coronary syndrome (Correia et al. 2009), and reduces the risk
after coronary interventions (Sattler et al. 2009), whereas some studies have shown
that HDL-C has no protective role in the secondary prevention of CHD after bypass
operation (Angeloni et al. 2013).
3 HDL Cholesterol as a Risk Factor for Other Diseases
The low level of HDL-C has been shown to be a risk factor for other diseases not
related to atherosclerosis. Recent reports have shown that HDL-C may be a
biomarker for diseases like psoriasis (Holzer et al. 2012), rheumatoid arthritis
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(Raterman et al. 2013), and liver fibrosis in hepatitis C patients (Gangadharan
et al. 2012). Alterations in HDL composition have been observed also in hemodial-
ysis patients (Mange´ et al. 2012).
Special interest has been recently focused on HDL in cancer patients. Several
epidemiological studies have shown that low HDL-C level may be a risk and/or
prognostic factor of biliary tract cancers (Andreotti et al. 2008), prostate cancer
(Mondul et al. 2011; Kotani et al. 2013), colon cancer (van Duijnhoven et al. 2011),
breast cancer (Furberg et al. 2005, Melvin et al. 2012) and gastric cancer (Tamura
et al. 2012), but not that of endometrial cancer (Cust et al. 2007; Esposito
et al. 2014) or rectal cancer (van Duijnhoven et al. 2011). Confounding factors
related to obesity and metabolic syndrome may be more strongly associated with
the latter cancer types (Kotani et al. 2013).
The association with low HDL-C levels is shared among many types of cancer,
and it is mainly linked to obesity and inflammation, suggesting a common pathway
(Melvin et al. 2013; Vı´lchez et al. 2014). The mechanism of cancer protection is not
known. Lipoprotein particles may carry cancerogenic molecules but at least one
small study has shown that persistent organogenic pollutants in HDL particles are
more associated with CVD than cancer (Ljunggren et al. 2014).
The potential importance of HDL particles in cancer protection has recently led
to attempts to develop cancer treatments by HDL-mimetic synthetic nanoparticles
(Zheng et al. 2013; Yang et al. 2013). These interesting approaches need to be
followed closely in the future.
4 Total HDL-C in Various Populations
Racial differences. Several studies have shown differences in HDL-C between
various ethnic groups (Thelle et al. 1982; Heiss et al. 1984; Haffner et al. 1986;
Saha 1987). The differences may in part be due to genetic factors but the role of
behavioral and anthropometric variables seem to affect the HDL-C (Thelle
et al. 1982; Haffner et al. 1986). Environmental factors such as diet, smoking,
and alcohol use may confound the differences observed between ethnic groups.
In the USA, the African-American population has higher HDL-C than
Caucasians after adjustment for weight, smoking, and alcohol consumption than
Caucasians (Heiss et al. 1984), while people originating from India have lower
HDL-C than Europeans or many other populations (Saha 1987; de Munter
et al. 2011). Differences in HDL-C and other lipoproteins between various ethnic
groups can be observed already in children (van Vliet et al. 2011). Even at an early
age, the HDL-C levels are confounded by other cardiovascular risk factors includ-
ing blood pressure, overweight, and obesity.
Gender differences. Women have higher HDL-C levels than men (Heiss
et al. 1980; Seidell et al. 1991), and significantly increased CHD risk is defined at
levels below 50 mg/dl (1.29 mmol/l) and 40 mg/dl (1.03 mmol/l), respectively. The
reason for the gender difference may mainly be sex hormones but the fat distribu-
tion seems to play a central role since adjustment for waist/thigh ratio almost totally
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removed the gender difference in HDL cholesterol (Seidell et al. 1991). In women
HDL-C levels decline after menopause (Heiss et al. 1980) but the sex difference
remains significant even in the seventh decade of life (Ostlund et al. 1990).
Age-related differences. Lipoprotein levels are very low at birth and then
increase during childhood. HDL-C levels decrease in males during puberty and
early adulthood and thereafter remain lower than those in women (Kreisberg and
Kasim 1987; Walter 2009). HDL-C levels decline with age and low HDL choles-
terol remains a powerful risk predictor into old age (Kreisberg and Kasim 1987;
Walter 2009). A selection bias by HDL-lowering genetic variation may explain
why HDL deficiency is rare among very old people (Kervinen et al. 1994; Baggio
et al. 1998).
5 Total HDL-C Modulated by Environmental Factors
Alcohol consumption in moderation is associated with a reduced risk for cardiovas-
cular diseases. Alcohol consumption increases the concentration of HDL-C, possi-
bly secondary to an inhibition of CETP (cholesteryl ester transfer protein)
(Savolainen et al. 1990; Hannuksela et al. 1992). A common polymorphism in
the CETP gene (TaqIB2) modifies the relationship of alcohol intake with HDL-C
suggesting a gene-environment interaction on the risk of CHD (Jensen et al. 2008).
However, it has not been definitely shown whether the HDL-C elevation associated
with alcohol consumption is cardioprotective.
The quantity of alcohol needed to increase HDL-C by 0.1 mmol/l (3.87 mg/dl) is
about 30 g/d (Brien et al. 2011). Therefore, alcohol drinking cannot be
recommended as a method to raise low HDL-C levels. The alcohol-induced
increase in HDL-C occurs commonly without significant changes in other lipids
although alcohol may increase triglyceride levels especially in subjects with ele-
vated triglyceride concentration.
The death rate from CHD among moderate alcohol users is lower than in total
abstainers or heavy drinkers (Rimm et al. 1999; Brien et al. 2011; Bergmann
et al. 2013). Even very low alcohol consumption, e.g., a couple of drinks per
week, seems to protect from CHD even though it does not have any significant
effect on HDL-C. To explain this fact, it has been suggested that ethanol metabo-
lism may produce specific bioactive lipids, e.g., phosphatidylethanol, that could
serve as a memory molecule in the body (Liisanantti et al. 2004). If HDL particles
of alcohol drinkers contain this bioactive lipid, it could circulate for several days
even without daily alcohol drinking, and when HDL enters into the endothelial cell,
it could then exert its positive effects on the vascular endothelium (Liisanantti and
Savolainen 2005). However, the concentration of phosphatidylethanol in HDL may
be in the low nanomolar range which makes the analysis challenging and may
hamper its determination of epidemiological studies.
Smoking reduces HDL-C level and smoking cessation is associated with an
increase in the plasma concentration of HDL-C (Maeda et al. 2003). The mecha-
nism by which smoking reduces HDL-C is not known. It is noteworthy that in many
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cases smoking is associated with alcohol drinking and therefore smoking could
attenuate the alcohol-induced increase in HDL-C.
Physical activity is associated with high HDL-C (Marti 1991). Low level of
physical activity is very common in the developed countries, and therefore, increas-
ing the level of exercise might be more beneficial for HDL-C than any other
preventive measure.
Education and socioeconomic status. HDL-C levels increase with income and
educational attainment after controlling diet, exercise, and other risk factors for
elevated cholesterol (Muennig et al. 2007). The mechanisms are not clear. It has
been suggested that stress differences by social class may play a role (Muennig
et al. 2007). However, several lifestyle factors including leisure-time physical
activity, smoking, alcohol drinking, and dietary habits correlate with the socioeco-
nomic status, classified as the degree of educational level (Schro¨der et al. 2004).
Dietary carbohydrates affect the lipoprotein profile. The epidemiological stud-
ies can be divided into three categories. First, the type of carbohydrate modulates
the impact of carbohydrates on plasma lipoproteins. The intake of refined
carbohydrates has increased in Western societies, and they have more deleterious
effects on abdominal obesity and consequently on insulin resistance and hepatic
lipogenesis in comparison with complex carbohydrates or starches (Ma et al. 2012;
Stanhope et al. 2009). The end result of high intake of refined carbohydrates is a low
HDL-C level (Heiss et al. 1980; Sonestedt et al. 2012).
Second, trials focusing on dietary carbohydrate restriction have shown modula-
tion of atherogenic dyslipidemia. The effect on HDL-C is modest but commonly
greater than that on total cholesterol, and thus, the atherogenic burden is improved.
Results from epidemiological studies are difficult to interpret due to differences in
diets.
The third type of studies involves the replacement of carbohydrate with different
fats in order to maintain isocaloric intake of macronutrients. A classic meta-
analysis of 60 trials (Mensink et al. 2003) showed that replacement of 10 % of
energy from carbohydrate with saturated fat, monounsaturated fat, and polyunsatu-
rated fat increased HDL-C by 4.7, 3.4, and 2.8 mg/dl (0.12, 0.09, and 0.07 mmol/l),
respectively. However, LDL cholesterol increased by 13 mg/dl (0.34 mmol/l) with
saturated fat substitution and decreased by 3.3 mg/dl (0.09 mmol/l) with polyunsat-
urated fat substitution while the substitution with monounsaturated fat had no effect
on LDL-C. Thus, the atherogenicity of the plasma lipoprotein profile improved with
the unsaturated fat substitution of carbohydrate.
The effects of dietary carbohydrates on HDL-C and CHD risk have been
analyzed also on the basis of their glycemic index (GI, the effect on blood glucose
level) or glycemic load (GL, including carbohydrate content and intake of foods in
addition to GI). High GL and GI were associated with significant increased risk of
CVDs, specifically for women. Several cross-sectional studies have reported
inverse associations of low GI and GL diets with HDL-C, but meta-analyses
(Kelly et al. 2004; Goff et al. 2013) have not found any effect on HDL-C.
Fatty acids and especially omega-3 fatty acids have been the focus of many
epidemiological studies. The most important omega-3 fatty acids in this respect are
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eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that increase
HDL-C by 1–3 % (Balk et al. 2006).
6 HDL-C in Diseases and Conditions
Type 2 diabetes. Patients with type 2 diabetes may have various types of
dyslipidemias that usually are accompanied with a low concentration of HDL-C
(Chehade et al. 2013; Morgantini et al. 2014). Low HDL-C contributes to diabetes-
related CHD risk more in women than in men, the diabetes-related hazard ratio for a
major CHD event being 3 times higher in women after adjustment for other
cardiovascular risk factors (Juutilainen et al. 2004). On the other hand, lipid
composition of HDL particles is associated with the development of metabolic
syndrome (Abbasi et al. 2013; Onat et al. 2013).
Dyslipidemias. Traditionally, dyslipidemia has been characterized by an eleva-
tion in plasma triglycerides and total or LDL cholesterol and reduction in HDL-C.
This is commonly referred to as the atherogenic triad. LDL particles are small and
dense (Mooradian 2009). Genetic studies have indicated linkage of apoB gene to
peak LDL size and plasma triglycerides, HDL-C, and apoB levels.
Obesity. Overweight and obese subjects usually have low HDL-C concentrations
(Seidell et al. 1991). The underlying cause may be insulin resistance that promotes
free fatty acid flux to the liver, stimulates hepatic lipogenesis, and finally enhances
the secretion of triglyceride-rich apoB-containing lipoproteins from the liver. The
excess triglyceride-rich particles also enhance the CETP-mediated exchange of
cholesteryl esters from HDL to apoB-containing lipoprotein particles and simulta-
neous transfer of triglycerides into HDL (Mann et al. 1991; Liinamaa et al. 1997).
This may further reduce HDL-C levels.
Weight reduction is an important modulator of the lipoprotein profile and long-
term weight reduction increases HDL-C levels especially in subjects with type
2 diabetes. It is noteworthy that the effect of weight reduction on HDL-C is
different in the initial weight loss period compared with the weight maintenance
phase. A meta-analysis has shown that HDL-C is increased by 0.35 mg/dl
(0.009 mmol/l) per kilogram weight lost during the stable weight reduction. During
active weight loss, however, HDL-C is reduced by 0.27 mg/dl (0.007 mmol/l) for
every kilogram of weight lost (Browning et al. 2011). Theoretically, an increase in
HDL-C of 2.45 mg/dl (0.06 mmol/l) could be expected during the stable weight
maintenance stage after a weight reduction of 7 % in an individual with an initial
weight of 100 kg. Furthermore, this would translate into 7.4 % reduction in CHD
risk in women.
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7 High HDL Levels Do Not Add to the Protection
While low levels of HDL-C are associated with increased CHD risk, high HDL-C
levels are not uniformly atheroprotective. At higher concentrations the curve of
CHD risk gradually tapers off as depicted in Fig. 1 which is based on the results
from the Framingham Heart Study (Gordon et al. 1977), and there is no additional
effect of higher HDL-C levels compared with average HDL-C concentrations.
8 Effect of HDL on Stroke
In contrast to the role of HDL-C as a major risk factor of CHD, the role of HDL-C in
the pathogenesis of ischemic stroke is less clear. Epidemiological studies of carotid
intima media thickness and stroke protection have provided conflicting results.
Even in the studies reporting positive results, the effect of HDL-C on protection
of stroke is modest (a 10 mg/dl or 0.38 mmol/l increase in HDL-C reduces stroke
risk by 11–15 %) compared with its protective effect on CHD. The discordant
results in prospective cohort studies as well as in case-control studies may be due to
the heterogeneity of stroke, since dyslipidemia including low HDL-C levels may
not be involved in the pathogenesis of some subtypes such as lacunar and
cardioembolic strokes (Amarenco et al. 2008).
Fig. 1 Potential differences in the functions of HDL particles. HDLaa depicts a theoretical
subclass of particles comprising the bulk of plasma HDL-C concentration but without any
significant role in reverse cholesterol transport or pleiotropic effects of HDL, whereas HDLbb
may be a smaller fraction but more active in reverse cholesterol transport. HDLcc could be a small
subclass without any significant contribution to the HDL-C quantity. These particles may, how-
ever, have many pleiotropic effects on cytokines, growth factors, etc. [Modified from Hannuksela
et al. (2004)]
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9 Time Trends in Total HDL-C
During the last decades, favorable trends in HDL-C levels have occurred in US
adults and youths aged 6–19 years despite changes in physical activity, obesity, and
diabetes (Carroll et al. 2012; Kit et al. 2012). Similar trends have been observed
also in Europe and India (Muntoni et al. 2009; Gupta et al. 2012).
10 Are There Other Biomarkers than the Total HDL-C?
The cholesterol in HDL (i.e., HDL-C) may reflect the rate of reverse cholesterol
transport from the peripheral tissues to liver. However, it may be that the bulk of
HDL cholesterol does not necessarily represent the particles that are involved in the
reverse cholesterol transport or any other potentially antiatherogenic activity of
HDL (Fig. 1).
HDL particles comprise a heterogeneous fraction of lipoprotein which vary by
the apolipoprotein and lipid content and consequently also in density, shape, size,
and charge. Various subfractions can be analyzed, e.g., by ultracentrifugation
(density), electron microscopy (shape), nondenaturing gel electrophoresis, gel
filtration or nuclear magnetic resonance (NMR) spectroscopy (size), NMR or
immunoaffinity (composition), and 2-dimensional electrophoresis (charge).
11 HDL Fractions
Analytic ultracentrifugation was first used to separate subclasses of HDL (DeLalla
et al. 1954). Later, the sequential ultracentrifugation and various precipitation
methods enabled the analysis of larger series in epidemiological studies.
Sequential ultracentrifugation methods have enabled separation of two major
HDL subfractions, namely, HDL2 and HDL3, while the isolation of further
subclasses has required more tedious methods such as gradient ultracentrifugation.
Nuclear magnetic resonance (NMR) spectroscopy has simplified the differentiation
into five subclasses. However, the nomenclature has varied and it is generally quite
difficult to compare HDL subclasses separated by different methods. Recently, a
unified nomenclature for a simplified differentiation into 5 subclasses according to
particle size (very small, small, medium, large, and very large HDL) has been
proposed (Rosenson et al. 2011).
Controversial results have been obtained in studies aimed at distinguishing
cardiovascular differences between HDL subclasses separated by density (Superko
et al. 2012; Pirillo et al. 2013). A majority of the studies, however, have found
HDL2-C to be more predictive of CHD risk than total HDL-C or HDL3-C
(Johansson et al. 1991; Drexel et al. 1992; Lamarche et al. 1997). A recent study
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with 29-year follow-up of the Gofman’s Livermore cohort showed that HDL2 and
HDL3 are independently related to CHD risk (Williams and Feldman 2011).
12 HDL Particle Size
Further characterization of HDL subfractions by nondenaturing polyacrylamide
gels has identified three HDL3 and two HDL2 subclasses. Very large HDL particles
(HDL2b subfraction with diameter between 9.7 and 12.9 nm) are strongly
correlated with the total HDL-C concentration and most strongly inversely related
to CHD risk in normotriglyceridemic subjects (Johansson et al. 1991). On the other
hand, an increased concentration small HDL particles (HDL3b subfraction, 7.8–
8.2 nm) is associated with an atherogenic lipoprotein profile characterized by low
HDL2b levels, high plasma triglyceride concentration, and increased level of small,
dense LDL particles (Berneis and Krauss 2002). Low concentration of HDL2b
subclass has also been shown in patients with T2DM (Xian et al. 2009).
13 HDL Particle Number
The complexity of HDL metabolism leads to the formation of multiple HDL
subpopulations with varying density, size, charge, and chemical composition.
Two individuals with the same HDL-C concentration may have HDL particles of
different size distribution, and consequently, the particle number is different.
Recently, NMR methods have enabled high-throughput determination of HDL
particle concentration. Plasma levels of large particles and low particle number
are consistently associated with low CHD prevalence (Mora et al. 2012).
14 HDL Lipids
Some of the effects of HDL on cellular functions are mediated by sphingomyelin-1-
phosphate (S1P) that is a bioactive lipid in HDL. Alterations in S1P content in HDL
particles could explain the dysfunction of HDL since the HDL-associated S1P
seems to be responsible for many of the pleiotropic effects of HDL by activating
special S1P receptors. In epidemiological studies low levels of S1P in HDL has
been associated with coronary heart disease (Argraves et al. 2011). Sphingomyelin
content in HDL particles has been associated with coronary heart disease in
postmenopausal women (Horter et al. 2002). Sphingomyelin has also been
associated with kidney disease in patients with type 1 diabetes (Ma¨kinen
et al. 2012).
Epidemiology: Disease Associations and Modulators of HDL-Related Biomarkers 269
15 HDL Apolipoproteins
The structure of HDL particles is very complex, apoA-I and apoA-II being the
major protein components. ApoA-I accounts for about two-thirds of the protein
content of HDL and is also functionally important since it is the acceptor in the
efflux of phospholipids and free cholesterol from peripheral cells. The measurement
of apolipoprotein levels is more expensive and time-consuming than that of lipid
concentrations. To circumvent this, data from large epidemiological cohorts was
recently used for the development of computer software that enables accurate
estimation of apolipoprotein levels on the basis of lipid measurements (Raitakari
et al. 2013).
High plasma levels of apoA-I are protective against atherosclerosis in some
studies (Arsenault et al. 2011; Emerging Risk Factor Collaboration 2012). It has
been proposed that apoA-I concentration could even be a better predictor of
atherosclerosis development than HDL-C. A recent study reported that adjustment
for apoA-I changes the direction of the association between HDL-C and the severity
of atherosclerotic lesions as determined with coronary artery calcium score (Sung
et al. 2013). Among patients treated with statin therapy, apoA-I levels are strongly
associated with a reduced cardiovascular risk, even among those achieving very
low LDL-C level (Boekholdt et al. 2013).
ApoA-II is the second major apolipoprotein in HDL particles. It is present in
most but not all particles and the clinical significance of apoA-II-containing and
apoA-II-free particles is controversial (Rosenson et al. 2011).
Some studies have reported enrichment with apoC-III in the HDL of patients
with CHD (Vaisar et al. 2010; Kavo et al. 2012; Jensen et al. 2012). Interestingly,
Jensen and coworkers found that HDL particles without apoC-III were inversely
associated with the risk of CHD while apoC-III-containing HDL particles were
directly associated with increased risk of CHD (Jensen et al. 2012). HDL with
apoC-III comprised about 13 % of the total HDL-C.
16 HDL Proteomics
Several proteins circulate attached to HDL particles although most of them in much
lower numbers than apolipoproteins mentioned above. The protein content of HDL
particles has been characterized recently using various methods commonly
described as proteomics. It has been shown that HDL2 fraction of CHD patients
carries a distinct protein cargo (Vaisar et al. 2010; Gordon et al. 2010; Kavo
et al. 2012; Alwaili et al. 2012).
Proteomics as a new promising approach for detecting biomarkers and
mechanisms could potentially explain the beneficial characteristics of HDL
particles unrelated to their cholesterol content. To this end, novel sophisticated
methods have been recently developed (Gordon et al. 2010; Mazur et al. 2010;
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Burillo et al. 2013; Hoofnagle et al. 2012; Mazur and Cardasis 2013; Riwanto
et al. 2013). High-throughput methods are urgently needed for large-scale epidemi-
ological studies.
17 HDL Function
Cholesterol efflux is the first step of reverse cholesterol transport. Excess cellular
cholesterol from peripheral tissues is effluxed to extracellular HDL-based acceptor
particles through the action of active transporters and passive diffusion. Recently, it
was reported that the cholesterol efflux measured from cultured macrophages
enriched with free cholesterol to apoB-depleted serum as cholesterol acceptor
was inversely associated with the history of CHD independent of HDL-C levels
(Khera et al. 2011). However, more recently, enhanced efflux has been associated
with high cardiovascular risk (Li et al. 2013). Further studies are urgently needed to
resolve the issue with conflicting results.
Antioxidative properties of HDL are mainly attributed to apoA-I although
paraoxonase 1 (PON1) may also play an important role. Antioxidative activity of
HDL subfractions increases with increment in density as follows:
HDL2b<HDL2a<HDL3a<HDL3b<HDL3c (Kontush et al. 2003). The determi-
nation of the antioxidative capacity of HDL particles is technically challenging, and
therefore, indirect approaches measuring arylesterase or paraoxonase activities
have been used in larger cohorts.
Molecules carried by HDL particles. Recent studies have shown that short
noncoding RNAs (microRNAs, miRNAs) are present in the circulation as a result
of cellular damage or secretion (Laterza et al. 2009). miRNAs are ideal biomarkers
since they are stable and their sequences can be easily amplified. Alterations in
circulating miRNA profiles have been associated with cardiovascular risk factors
such as hypertension, diabetes, and dyslipidemias as well as with cardiovascular
diseases such as coronary heart disease, myocardial infarction, and heart failure
(Fichtlscherer et al. 2011; de Rosa et al. 2011). However, this association has not
been found in all studies (Wagner et al. 2013).
Several proteins are also attached to HDL particles. Paraoxonase 1 (PON1) is an
HDL-associated enzyme that has been suggested to mediate many antiatherogenic
and cardioprotective effects of HDL particles (Mackness et al. 2004; Aviram and
Vaya 2013).
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18 Pleiotropy
In addition to the antioxidative properties HDL particles have also other functions
independent of the effects of HDL particles on cholesterol homeostasis. These
include anti-inflammatory, anti-infective, antithrombotic, and endotoxin-
neutralizing effects as well as effects on endothelial function. These pleiotropic
effects have been recently reviewed (Annema and von Eckardstein 2013). The
laboratory assays used for analyzing the pleiotropic effects of HDL are demanding
and need to be standardized before they can be used in large epidemiological
studies in order to improve the CHD risk assessment.
19 Future Approaches of Epidemiological Studies
New approaches have been used in order to resolve the complex effects of diseases,
conditions, environmental factors, and genes in relation to the protective role of HDL.
On one hand, there have been efforts to dissect the HDL fraction into as many well-
defined subfractions and individual molecules of HDL particles as possible. On the
other hand, as discussed above, the focus has been shifted from the structure and
composition to the function of HDL particles (Fig. 2). Moreover, recent development
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Fig. 2 Relation between HDL-C and risk of myocardial infarction. The solid curve shows the
average risk level by HDL-C concentration. The risk of individuals, however, may vary substan-
tially, and even at the same HDL-C level, the CHD risk could be anywhere between the dotted
lines. Furthermore, the nearly horizontal arrow depicts how previous approaches have attempted
to improve the atheroprotective capacity of HDL by increasing the quantity of HDL-C. Nowadays,
several studies have suggested that it might be more important to change the quality of HDL
particles as shown by the arrow down. Various biomarkers and function assays have been
commonly used to determine the improved quality that ultimately could lead to lower risk of
myocardial infarction
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the analysis of more holistic patterns on lipoproteins and subfractions and their
relation to the risk of CHD (Ala-Korpela 2008; Rosenson et al. 2011; Wu¨rtz
et al. 2012).
Dietary patterns have been used as a complementary approach to the traditional
single-nutrient analysis (Randall et al. 1990; Bogl et al. 2013). Dietary patterns are,
e.g., “fruit and vegetables,” “meat,” “sweets and desserts,” “junk food,” and “fish.”
The “junk food” pattern is characterized by higher intakes of energy-dense nutrient-
poor foods, such as hamburger, pizza, French fries, salty snacks, and liquorices and
lower intakes of porridge, rye bread, and fruit. The “junk food” pattern
distinguishes from the commonly used definition of “Western pattern” in that
“junk food” does not contain high amounts of meat, eggs, or high-fat dairy. The
healthy diet pattern has been associated with higher levels of HDL-C, whereas the
fast-food dietary pattern, high in saturated fat, did not have this effect (Hamer and
Mishra 2010).
The idea of analyzing the whole diet through dietary patterns is based on the fact
that people do not eat single purified nutrients or simple foods, but mixed meals
consisting of several foods and nutrients at a time. The term “nutritional epidemi-
ology” depicting food patterns was coined already in the 1970s (Krehl 1977) but has
only recently used more frequently.
The Mediterranean diet refers to a dietary profile commonly available in the
early 1960s in the Mediterranean regions and characterized by a high consumption
of fruit, vegetables, legumes, and complex carbohydrates, with a moderate con-
sumption of fish, and the consumption of olive oil as the main source of fats and a
low-to-moderate amount of red wine during meals (Sofi et al. 2010). A recent meta-
analysis of 50 studies summarized the impact of the Mediterranean diet on CHD
risk factors (Kastorini et al. 2011). The diet is associated with a 3 % increase in
HDL-C, but many other lipid and non-lipid risk factors such as hypertrigly-
ceridemia, blood pressure, glucose, insulin resistance, and abdominal obesity are
also affected.
Conclusion
HDL-C is a strong and independent predictor of major cardiovascular events in a
wide range of populations, in men and women with or without preceding CHD.
As molecular biology and related approaches have revealed new biomarkers or
profiles in HDL structure and function, the epidemiological research is also
moving from the classical determination of total HDL-C to structure-function
analyses. Recent methodological breakthroughs in HDL structure analyses have
enabled their use also in large cohorts. In the future, further investigations are
urgently needed for validation and clinical applications of HDL function assays.
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